BioSpace News Archive

Atara Biotherapeutics, Inc. today announced new preclinical and preliminary clinical results for ATA2271, a next-generation autologous chimeric antigen receptor (CAR) T-cell therapy targeting mesothelin (MSLN).

VBI Vaccines Inc. today announced the filing of a New Drug Submission (NDS) to Health Canada for the Company’s 3-antigen prophylactic hepatitis B vaccine candidate, seeking approval in Canada for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults.

Inspirna, Inc. announced today the appointment of Josep Tabernero, M.D., Ph.D. and Alan P. Venook, M.D., to its scientific advisory board.

Rheos Medicines today announced that company management will participate in a fireside chat at the 2021 RBC Capital Markets Healthcare Private Company Conference on Thursday, December 16, 2021 at 11:20 a.m. ET.

NextVivo , a biotech company developing an immune organoid technology platform, emerged from stealth today with $7.9M in financing led by Khosla Ventures, with participation from Alexandria Venture Investments, Wilson Sonsini, and individual investors.

Sesen Bio today announced its anticipated regulatory path forward for Vicineum™ or the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) following its Clinical Type A meeting with the US Food and Drug Administration (FDA), which occurred on December 8, 2021 (Clinical Type A Meeting).

Dermavant Announces Publication of PSOARING 1 & 2 Pivotal Studies of Tapinarof in Plaque Psoriasis in The New England Journal of Medicine.

Global spending on medicines — based on invoice price levels — is expected to grow at 3-6% CAGR through 2026 to reach about $1.8 trillion by 2026, including spending on COVID-19 vaccines and novel therapeutics, according to a new report, The Global Spending and Usage of Medicines, released by the IQVIA™ Institute for Human Data Science.

Agendia Presents Data at SABCS 2021 Showing MammaPrint ® and BluePrint ® More Robustly Identify Genomic Differences in HR+ HER2- Breast Cancers in Black and White Women Beyond Clinical Factors.

BlueCube Bio officially announced a company name transition to Evia Bio™, concurrent with the launch of a significant new cryopreservation technology for use in cell and gene therapies utilizing Induced Pluripotent Stem Cells (iPSCs).